

鄧 豪 偉

最高學歷


國立陽明大學醫學士

國立陽明大學臨床醫學研究所博士

現職：

台北榮民總醫院腫瘤醫學部腫瘤內科主治醫師

國立陽明交通大學教授



個人網站：



大腸直腸癌即時照護網 <https://crc.uptocare.com>

皮膚即時照護網 <https://skin.uptocare.com>

癌症統計互動網站 <https://uptocare.shinyapps.io/uptocarestat/>

建置：國立陽明交通大學 宜蘭附設醫院 資料整合計畫網站(2023/10)

專長：

臨床：大腸直腸癌 肛門癌 皮膚癌

研究：整合 Wet and Dry laboratory studies

生物資資及程式：Java, Web-app (Tomcat/JSP), Python, MS-SQL, Power BI,
R program/Shiny server, SAS, SPSS, TCGA Data, cBioportal, Google
analytics。

經歷：

1991-1998 國立陽明大學醫學系

1998-2000 桃園榮民總醫院內科部住院醫師(公費服務)

2000-2003 台北榮民總醫院內科部住院醫師

2003-2007 台北榮民總醫院內科部血液腫瘤科住院總醫師

2007~迄今：台北榮民總醫院內科部血液腫瘤科主治醫師

專科證書

中華民國內科專科醫師

中華民國血液病專科醫師

中華民國腫瘤內科專科醫師

中華民國安寧緩和專科醫師

專科學會

中華民國內科醫學會

中華民國血液病醫學會

中華民國癌症醫學會

中華民國安寧緩和醫學會

著作：

1. Surgical strategy for colorectal cancer with synchronous liver and extrahepatic metastases: A scoring system and decision tree model. Tseng CW, Teng HW, Lin CC, Lei HJ, Hung JJ, Liang WY, Hsia CY, Chou SC, Lin HH, Huang SC, Cheng HH, Lan YT, Wang HS, Yang SH, Chen WS, Lin JK, Jiang JK, Chang SC, Chau GY. *J Chin Med Assoc.* 2023 Aug 1;86(8):732
2. Anti-VEGF Therapy Possibly Extends Survival in Patients With Colorectal Brain Metastasis by Protecting Patients From Neurologic Disability. Chen CW, Ou TS, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Huang SC, Cheng HH, Yang YW, Lin YZ, Chao Y, Wang LW, Teng HW. *Clin Colorectal Cancer.* 2023 Mar 28:S1533-0028(23)00034-8
3. Molecular actions of exosomes and their theragnostics in colorectal cancer: current findings and limitations. Lin WC, Lin CC, Lin YY, Yang WH, Twu YC, Teng HW, Hwang WL. *Cell Oncol (Dordr).* 2022 Sep 1. doi: 10.1007
4. A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer. Huang SC, Lin CC, Teng HW, Lin HH, Chang SC, Lan YT, Wang HS, Yang SH, Chen WS, Jiang JK. *Front Oncol.* 2022 Mar 17;12:808808. doi: 10.3389/fonc.2022.808808. eCollection 2022.
5. Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment. Chen HH, Ke TW, Huang CW, Jiang JK, Chen CC, Hsieh YY, Teng HW, Lin BW, Liang YH, Su YL, Hsu HC, Kuan FC, Chou YH, Lin J, Lin BR, Chang YY, Wang JY. *Front Oncol.* 2021 Nov 15;11:764912
6. Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan. Yeh KH, Yang TS, Hsu TC, Tzu-Liang Chen W, Chen HH, Teng HW, Lin BW, Kuan FC, Chiang FF, Duann CW, Li YS, Lin MT, Fiala-Buskies S, Ducreux M, Wang JY. *J Formos Med Assoc.* 2021 Nov;120(11):2023-2031
7. The efficacy of anti-EGFR therapy in treating metastatic colorectal cancer differs between the middle/low rectum and the left-sided colon. Lee KH, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Huang SC, Cheng HH, Chao Y, Teng HW. *Br J Cancer.* 2021 Jun 29.
8. Insulin-Like Growth Factor 2 mRNA-Binding Protein 1 (IGF2BP1) Is a Prognostic Biomarker and Associated with Chemotherapy Responsiveness in Colorectal Cancer. Chen HM, Lin CC, Chen WS, Jiang JK, Yang SH, Chang SC, Ho CL, Yang CC, Huang SC, Chao Y, Liao TT, Hwang WL, Teng HW. *Int J Mol Sci.* 2021 Jun 28;22(13):6940. doi: 10.3390/ijms22136940. PMID: 34203267 Free PMC article.

9. Acrolein contributes to human colorectal tumorigenesis through the activation of RAS-MAPK pathway. Tsai HC, Tsou HH, Lin CC, Chen SC, Cheng HW, Liu TY, Chen WS, Jiang JK, Yang SH, Chang SC, Teng HW, Wang HT. *Sci Rep*. 2021 Jun 15;11(1):12590. doi: 10.1038/s41598-021-92035-z.
10. Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan. Yeh KH, Yang TS, Hsu TC, Tzu-Liang Chen W, Chen HH, Teng HW, Lin BW, Kuan FC, Chiang FF, Duann CW, Li YS, Lin MT, Fiala-Buskies S, Ducreux M, Wang JY. *J Formos Med Assoc*. 2021 Jan 6:S0929-6646(20)30615-X.
11. Significance of Kynurenine 3-Monooxygenase Expression in Colorectal Cancer. Liu CY, Huang TT, Chen JL, Chu PY, Lee CH, Lee HC, Lee YH, Chang YY, Yang SH, Jiang JK, Chen WS, Chao Y, Teng HW. *Front Oncol*. 2021 Apr 16;11:620361.
12. In Reply: Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer. Teng HW. *Am J Clin Oncol*. 2020 Dec 1;43(12):905-906.
13. Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan. Yeh KH, Yang TS, Hsu TC, Tzu-Liang Chen W, Chen HH, Teng HW, Lin BW, Kuan FC, Chiang FF, Duann CW, Li YS, Lin MT, Fiala-Buskies S, Ducreux M, Wang JY. *J Formos Med Assoc*. 2021 Jan 6:S0929-6646(20)30615-X.
14. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, de la Fouchardiere C, Rivera F, Elez E, Bendell J, Le DT, Yoshino T, Van Cutsem E, Yang P, Farooqui MZH, Marinello P, Diaz LA Jr; KEYNOTE-177 Investigators. *N Engl J Med*. 2020 Dec 3;383(23):2207-2218.
15. Effect of Primary Tumor Location on Postmetastasectomy Survival in Patients with Colorectal Cancer Liver Metastasis. Chen TH, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Huang SC, Cheng HH, Chau GY, Hsia CY, Lei HJ, Chou SC, Chao Y, Teng HW. *J Gastrointest Surg*. 2020 Nov 17. doi: 10.1007/s11605-020-04855-5. Online ahead of print.
16. Harnessing stemness and PD-L1 expression by AT-rich interaction domain-containing protein 3B in colorectal cancer. Liao TT, Lin CC, Jiang JK, Yang SH, Teng HW, Yang MH. *Theranostics*. 2020 May 15;10(14):6095-6112. doi: 10.7150/thno.44147. eCollection 2020.

17. Aspirin and Risk of Dementia in Patients with Late-Onset Depression: A Population-Based Cohort Study. Yang YH, Chiu CC, Teng HW, Huang CT, Liu CY, Huang LJ. *Biomed Res Int*. 2020 Jan 29;2020:1704879.
18. Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer. Tai CC, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Huang SC, Cheng HH, Chao Y, Teng HW. *Am J Clin Oncol*. 2020 Jan;43(1):28
19. Planned Short-Course Radiation (scRT) is Superior to Upfront Concurrent Chemoradiation (CCRT) in Treating Metastatic Rectal Cancer. **Teng HW***, Lin JK, Lin TC, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Huang SC. *J Gastrointest Surg*. 2019 May 28. doi: 10.1007/s11605-019-04256-3. [Epub ahead of print]
20. PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1. Ho HL, Chou TY, Yang SH, Jiang JK, Chen WS, Chao Y, **Teng HW***. *J Cancer Res Clin Oncol*. 2019 Jul;145(7):1785-1794. doi: 10.1007/s00432-019-02942-y. Epub 2019 May 25.
21. A phase 0 study of the pharmacokinetics, biodistribution, and dosimetry of ¹⁸⁸Re-liposome in patients with metastatic tumors. Wang SJ, Huang WS, Chuang CM, Chang CH, Lee TW, Ting G, Chen MH, Chang PM, Chao TC, **Teng HW**, Chao Y, Chen YM, Lin TP, Chang YJ, Chen SJ, Huang YR, Lan KL. *EJNMMI Res*. 2019 May 22;9(1):46. doi: 10.1186/s13550-019-0509-6.
22. RAB27B-activated secretion of stem-like tumor exosomes delivers the biomarker microRNA-146a-5p, which promotes tumorigenesis and associates with an immunosuppressive tumor microenvironment in colorectal cancer. Cheng WC, Liao TT, Lin CC, Yuan LE, Lan HY, Lin HH, **Teng HW**, Chang HC, Lin CH, Yang CY, Huang SC, Jiang JK, Yang SH, Yang MH, Hwang WL. *Int J Cancer*. 2019 Apr 13. doi: 10.1002/ijc.32338. [Epub ahead of print]
23. ER stress-related ATF6 upregulates CIP2A and contributes to poor prognosis of colon cancer. Liu CY, Hsu CC, Huang TT, Lee CH, Chen JL, Yang SH, Jiang JK, Chen WS, Lee KD, **Teng HW***. *Mol Oncol*. 2018 Oct;12(10):1706-1717
24. Intraperitoneal ziv-aflibercept effectively manages refractory ascites in colorectal cancer patients. Lu CS, Lin JK, Chen WS, Lin TC, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, **Teng HW***. *Oncotarget*. 2016 Nov 24
25. Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma. **Teng HW**, Hung MH, Chen LJ, Chang MJ, Hsieh FS, Tsai MH, Huang JW, Lin CL, Tseng HW, Kuo ZK, Jiang JK, Yang SH, Shiau CW, Chen KF. *Sci Rep*. 2016 Oct 18;6:35308.

26. Adjuvant FOLFOX treatment for stage III colon cancer: how many cycles are enough? Tsai YJ, Lin JK, Chen WS, Jiang JK, Teng HW, Yen CC, Lin TC, Yang SH. Springerplus. 2016 Aug 11;5(1):1318. doi: 10.1186/s40064-016-2976-9. eCollection 2016.
27. Primary tumor location is an important predictive factor for wild-type KRAS metastatic colon cancer treated with cetuximab as front-line bio-therapy. Lu HJ, Lin JK, Chen WS, Jiang JK, Yang SH, Lan YT, Lin CC, Chang SC, **Teng HW*** Asia Pac J Clin Oncol. 2016 Sep;12(3):207-15. doi: 10.1111/ajco.12469. Epub 2016 Mar 3.
28. Pharmacological Targeting SHP-1-STAT3 Signaling Is a Promising Therapeutic Approach for the Treatment of Colorectal Cancer. Fan LC, **Teng HW*(co-first author)**, Shiau CW, Tai WT, Hung MH, Yang SH, Jiang JK, Chen KF. Neoplasia. 2015 Sep;17(9):687-96. doi: 10.1016/j.neo.2015.08.007.
29. Statins Reduces the Risk of Dementia in Patients with Late-Onset Depression: A Retrospective Cohort Study. Yang YH, **Teng HW*(co-first author)**, Lai YT, Li SY, Lin CC, Yang AC, Chan HL, Hsieh YH, Lin CF, Hsu FY, Liu CK, Liu WS. PLoS One. 2015 Sep 18;10(9)
30. Incidence of Second Primary Malignancies Following Colorectal Cancer: A Distinct Pattern of Occurrence Between Colon and Rectal Cancers and Association of Co-Morbidity with Second Primary Malignancies in a Population-Based Cohort of 98,876 Patients in Taiwan. Lee YT, Liu CJ, Hu YW, Teng CJ, Tzeng CH, Yeh CM, Chen TJ, Lin JK, Lin CC, Lan YT, Wang HS, Yang SH, Jiang JK, Chen WS, Lin TC, Chang SC, Chen MH, Teng HW, Liu JH, Yen CC. Medicine (Baltimore). 2015 Jul;94(26)
31. The Prognostic Role of Para-Aortic Lymph Nodes in Patients with Colorectal Cancer: Is It Regional or Distant Disease? Lu HJ, Lin JK, Chen WS, Jiang JK, Yang SH, Lan YT, Lin CC, Liu CA, **Teng HW***. PLoS One. 2015 Jun 26;10(6):e0130345. doi: 10.1371/journal.pone.0130345. eCollection 2015.
32. Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an independent prognostic marker in wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy. Chen KF, Yen CC, Lin JK, Chen WS, Yang SH, Jiang JK, Lan YT, Lin CC, Yu HC, Hsu HM, Lin WL, **Teng HW***.
33. Reduced-intensity FOLFOXIRI in Treating Refractory Metastatic Colorectal Cancer: A pilot study Chen HM, Lin JK, Chen WS, Jiang JK, Yang SH, Lan YT, Lin CC, **Teng HW***. Am J Clin Oncol. 2014 Oct 20. [Epub ahead of print]
34. Comparison of Cetuximab to Bevacizumab as the First-line Bio-chemotherapy for Patients with Metastatic Colorectal Cancer: Superior Progression-free Survival is Restricted to Patients with Measurable Tumors and Objective Tumor

- Response - A Retrospective Study. Yuan-Hao Yang, Jen-Kou Lin, Wei-Shone Chen, Tzu-Chen Lin, Shung-Haur Yang, Jeng-Kai Jiang, Yuan-Tzu Lan, Chun-Chi Lin, Chueh-Chuan Yen, Cheng-Hwai Tzeng, **Hao-Wei Teng*** J Cancer Res Clin Oncol. J Cancer Res Clin Oncol. 2014 Jun 17
35. Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism. Wang HW, Yang SH, Huang GD, Lin JK, Chen WS, Jiang JK, Lan YT, Lin CC, Hwang WL, Tzeng CH, Li AF, Yen CC, **Teng HW***. J Cancer Res Clin Oncol. 2014 Apr;140(4):561-71.
 36. Prognostic significance of C-reactive protein polymorphism and KRAS/BRAF in synchronous liver metastasis from colorectal cancer. Huang CJ, **Teng HW**, Chien CC, Lin JK, Yang SH. PLoS One. 2013 Jun 3;8(6)
 37. Concurrent Chemoradiotherapy Followed by Metastasectomy Converts to Survival Benefit in Stage IV Rectum Cancer. Jen-Kou Lin, M.D., Lin-Kun Lee, M.D., Wei-Shone Chen, M.D., Tzu-Chen Lin, M.D. Jeng-Kai Jiang, M.D., Shung-Haur Yang, M.D., Huann-Sheng Wang, M.D., Shih-Ching Chang, M.D., Yuan-Tzu Lan, M.D., Chun-Chi Lin, M.D., Chueh-Chuan Yen, M.D., Jin-Hwang Liu, M.D., Cheng-Hwai Tzeng, M.D. **Hao-Wei Teng***, M.D. Gastrointest Surg. 2012 June acceptance
 38. CIP2A Is a Predictor of Poor Prognosis in Colon Cancer. **Hao-Wei Teng**, Shung-Haur Yang, Jen-Kou Lin, Wei-Shone Chen, Tzu-Chen Lin, Jeng-Kai Jiang, Chueh-Chuan Yen; Anna Fen-Yau Li, Paul Chih-Hsueh Chen, Yuan-Tzu Lan, Chun-Chi Lin, Yen-Ning Hsu, Hsei-Wei Wang, Kuen-Feng Chen* Gastrointest Surg. 2012 May;16(5):1037-47
 39. BRAF Mutation is a Prognostic Biomarker for Colorectal Liver Metastasectomy. **Hao-Wei Teng**, Yu-Chung Huang, Jen-Kou Lin, Wei-Shone Chen, Tzu-Chen Lin, Jeng-Kai Jiang, Chueh-Chuan Yen, Anna Fen-Yau Li, Hsei-Wei Wang, Shih-Ching Chang, Yuan-Tzu Lan, Chun-Chi Lin, Huann-Sheng Wang, Shung-Haur Yang* J Surg Oncol. 2012 Aug 1;106(2):123-9
 40. A new classification scheme for recurrent or metastatic colon cancer after liver metastasectomy. Hsu YN, Lin JK, Chen WS, Lin TC, Yang SH, Jiang JK, Chang SC, Yen CC, Tzeng CH, **Teng HW***. J Chin Med Assoc. 2011 Nov;74(11):493-9.
 41. The efficacy of chemotherapy in patients with high-grade metastatic colon cancer. Liu CJ, Lin JK, Chen WS, Lin TC, Yang SH, Jiang JK, Chang SC, Lan YT, Yen

- CC, Tzeng CH, Wang HW, **Teng HW***. Hepatogastroenterology. 2011 Sep-Oct;58(110-111):1495-501. doi: 10.5754/hge11082. Epub 2011 Jul 15.
42. Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study.
Yang YH, Lin JK, Chen WS, Lin TC, Yang SH, Jiang JK, Chang SC, Lan YT, Lin CC, Yen CC, Tzeng CH, Wang WS, Chiang HL, Teng CJ, **Teng HW***. Support Care Cancer. 2012 Jul;20(7):1491-7.
43. Liver abscess after liver metastasectomy is a poor prognostic factor in patients with colorectal cancer.
Hsu YN, Liu CJ, Lin JK, Chen WS, Lin TC, Yang SH, Jiang JK, Chang SC, Lan YT, Lin CC, Yen CC, Liu JH, Tzeng CH, **Teng HW***. J Gastrointest Surg. 2011 Oct;15(10):1798-806. Epub 2011 Jul 23.
44. Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma.
Huang YC, Liu CJ, Liu CY, Pai JT, Hong YC, Teng HW, Hsiao LT, Chao TC, Gau JP, Liu JH, Hsu HC, Chiou TJ, Chen PM, Yu YB, Tzeng CH*. Ann Hematol. 2011 Oct;90(10):1145-51. Epub 2011 Jun 7.
45. SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells.
Hwang WL, Yang MH, Tsai ML, Lan HY, Su SH, Chang SC, Teng HW, Yang SH, Lan YT, Chiou SH, Wang HW. Gastroenterology. 2011 Jul;141(1):279-91, 291.e1-5. Epub 2011 Apr 16.
46. Effective salvage therapy of imatinib-resistant gastrointestinal stromal tumor with combination of imatinib and pegylated liposomal doxorubicin.
Hsieh YY, Yen CC, Yeh CN, Tzen CY, Liu JH, Lee HJ, Teng HW, Tzeng CH, Chiou TJ, Chao TC. J Chin Med Assoc. 2011 Jun;74(6):272-4. Epub 2011 May 13.
47. International Staging System predicts prognosis of Chinese patients with multiple myeloma across different calendar periods with application of novel agents.
Yang SH, Teng HW, Hong YC, Liu CY, Yu YB, Yang CF, Gau JP, Liu JH, Chang TJ, Yen JJ, Chen PM, Chiou TJ, Tzeng CH, Hsiao LT. Ann Hematol. 2012 Jan;91(1):93-102. Epub 2011 May 17.
48. Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma.

Teng HW*, Wang HW, Chen WM, Chao TC, Hsieh YY, Hsieh CH, Tzeng CH, Chen PC, Yen CC. *J Surg Oncol*. 2011 Jun;103(8):773-81. doi: 10.1002/jso.21852. Epub 2011 Jan 15.

49. Pneumothorax after bevacizumab-containing chemotherapy: a case report.
Yang SH, Lin JK, Chen WS, Lin TC, Yang SH, Jiang JK, Chang SC, Lan YT, Chao TC, Yen CC, Tzeng CH, **Teng HW***. *Jpn J Clin Oncol*. 2011 Feb;41(2):269-71. Epub 2010 Oct 28.
50. Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.
Liu JH, Hsieh YY, Chen WS, Hsu YN, Chau GY, Teng HW, King KL, Lin TC, Tzeng CH, Lin JK. *Int J Colorectal Dis*. 2010 Oct;25(10):1243-9.
51. High early mortality rate in elderly patients with multiple myeloma receiving a vincristine-doxorubicin-dexamethasone regimen.
Teng HW*, Teng CJ, Wang WS, Chen PM, Chiou TJ, Hsu HC, Liu JH, Yen CC, Hsiao LT, Yang MH, Chao TC, Yang YH, Gau JP. *Am J Hematol*. 2010 Oct;85(10):812-5.
52. Diabetes mellitus negatively impacts survival of patients with colon cancer, particularly in stage II disease.
Huang YC, Lin JK, Chen WS, Lin TC, Yang SH, Jiang JK, Chang SC, Lan YT, Wang HS, Liu CY, Yang YW, **Teng HW***. *J Cancer Res Clin Oncol*. 2011 Feb;137(2):211-20. Epub 2010 Apr 13.
53. Sustained remission and long-term survival of secondary central nervous system involvement by aggressive B-cell lymphoma after combination treatment of systemic high-dose chemotherapy and intrathecal rituximab.
Liu CY, Teng HW, Lin JF, Chiou TJ, Chen PM, Hsiao LT. *Leuk Lymphoma*. 2008 Oct;49(10):2018-21. No abstract available.
54. Methotrexate and leucovorin double-modulated 5-fluorouracil combined with cisplatin (MPFL) in metastatic/recurrent head and neck cancer.
Chang PM, Teng HW, Chen PM, Chang SY, Chu PY, Tsai TL, Tai SK, Wang YF, Huang JL, Yang MH. *J Chin Med Assoc*. 2008 Jul;71(7):336-41.
55. High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin's lymphoma.
Chen MH, Hsiao LT, Chiou TJ, Liu JH, Gau JP, Teng HW, Wang WS, Chao TC, Yen CC, Chen PM. *Ann Hematol*. 2008 Jun;87(6):475-80. Epub 2008 Mar 8.

56. Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation.
Lee MY, Chiou TJ, Hsiao LT, Yang MH, Lin PC, Poh SB, Yen CC, Liu JH, Teng HW, Chao TC, Wang WS, Chen PM. Ann Hematol. 2008 Apr;87(4):285-9. Epub 2007 Oct 18.
57. The prolonged activated partial thromboplastin time at diagnosis indicates less favorable prognosis in IgA myeloma.
Teng HW, Chen PM, Yang YH, Gau JP. Jpn J Clin Oncol. 2007 Aug;37(8):609-14. Epub 2007 Aug 11.

CURRICULUM VITAE

1. PERSONAL DATA

Sheng-Chieh Huang, M.D. PhD
Gender: Male
Date of Birth: September 21, 1983
Country: Taiwan (Republic of China)
Address: Division of Colon & Rectal Surgery, Department of
Surgery, Taipei Veterans General Hospital, No 201, Sec
2, Shih-Pai Rd 11217 Taipei, Taiwan (Republic of
China)
Phone: 886-2-28757544-9
Fax: 886-2-28757639
E-mail: tmuholier@gmail.com



2. EDUCATION

M.D. 09/2002-06/2009: School of Medicine, College of Medicine, Taipei Medical
University, Taipei, Taiwan
PhD 09/2017- 02/2024: Institute of Clinical Medicine, National Yang-Ming University
Title of thesis: Novel Insights into CEACAM5 Gene Methylation in Colorectal
Cancer and Its Clinical Relevance

3. POSITION and TRAINING

01/2021-12/2021 Deputy Secretary-general, Society of Colon and Rectal surgeons, Taiwan
01/2018-12/2019 Deputy Secretary-general, Society of Colon and Rectal surgeons, Taiwan
07/2015-Present: Attending physician, Division of Colon & Rectal Surgery, Department of
Surgery, Taipei Veteran General Hospital, Taipei, Taiwan
01/2015-06/2015: Chief resident, Division of Colon & Rectal Surgery, Chang Gung
Memorial Hospital, Linko, Taiwan
07/2014-12/2014: Chief resident, Division of Colon & Rectal Surgery, Department of
Surgery, Taipei Veteran General Hospital, Taipei, Taiwan
08/2010-06/2014: Resident, Division of Colon & Rectal Surgery, Department of Surgery,
Taipei Veteran General Hospital, Taipei, Taiwan
07/2009-07/2010: Military service
06/2008-06/2009: Intern, Taipei Veteran General Hospital, Taipei, Taiwan
05/2006-06.2007 Research exchange in Pharmacy department of National Health Research
Institutes, Taipei, Taiwan

4. FACULTY

2016/08-Present Lecturer, Faculty of Medicine, School of Medicine, National Yang-Ming
University, Taiwan.

5. SPECIALTY

- (1) Colon and rectal disease
- (2) Minimal invasive surgery
- (3) Colonscopy

6. ACADEMIC AFFILIATION

2014~, Member, Taiwan Surgical Association, R.O.C.

2015~, Member, Society of Colon and Rectal Surgeons, Taiwan, R.O.C.

2015~, Member, Taiwan Surgical Society of Gastroenterology, R.O.C.

7. ORAL PRESENTATION

1. 11/2011 The Annual meeting of Society of Colon and Rectal surgeons, Taiwan
Topic: Case Series About Early Colorectal Cancer Patients with Extremely High CEA Level
2. 03/2013 The Annual Meeting of Taiwan Surgical Association, Taiwan
Topic: CEA ratio could be a prognostic Surrogate Indicators of Metastatic Colorectal Cancer Patients Treated with Chemotherapy
3. 09/2014 The 26th Biennial Congress of The International Society of University Colon & Rectal Surgeons, South Africa.
Topic: CEA Ratio and Response Evaluation Criteria in Solid Tumors as Prognostic Surrogate Indicators of Metastatic Colorectal Cancer Patients Treated with Chemotherapy
4. 09/2016 Annual Meeting of the Society of Colon and Rectal Surgeons, Taiwan
Topic: The results of confliction between carcinoembriogenic antigen and image follow up of metastatic colorectal cancer patients treated with chemotherapy
5. 12/2017 Annual Meeting of the Society of Colon and Rectal Surgeons, Taiwan
Topic: The effects of the procedure to close the peritoneal defect after the minimal invasive colorectal surgery
6. 12/2018 Annual Meeting of the Society of Colon and Rectal Surgeons, Taiwan
Topic: Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: when and how
7. 11/2020:Kaohsuing Medical University Hospital International Cancer and Long-term Symposium
Topic :Therapeutic strategies of bevacizumab with different chemo-partners in first and second line to improve the continuum of care in mCRC
8. 11/2021 18th Congress of Asia Pacific Federation of Coloproctology
35th Society of Colon and Rectal Surgeons congress
Topic : Second Look Polypectomy for High-Risk Colorectal Cancer
Topic : Optimize mCRC Patient's Survival under NHI in Taiwan
9. 12/2022 Annual Meeting of the Society of Colon and Rectal Surgeons, Taiwan
Topic : Decision Making Upon the mCRC Treatment Strategy in Taiwan
- 10.12/2023 Annual Meeting of the Society of Colon and Rectal Surgeons, Taiwan
Topic: RWD for CRC Treatment Landscape in NHI Database
Topic: How to select the Right patient for HIPEC therapy
- 11.12/2024 Annual Meeting of the Society of Colon and Rectal Surgeons, Taiwan
Topic : Evaluating Bevacizumab in the Treatment of Metastatic Colorectal Cancer :Insights from Clinical Trials and Real-World Evidence
Topic : Experience sharing on HIPEC treatment at Taipei Veterans General Hospital : Policy adjustment, tips and future Development

8. PUBLICATION

1. **Huang SC**, Lin JK, Lin TC, Chen WS, Yang SH, Wang HS, Lan YT, Lin CC, Jiang JK, Chang SC. Concordance of Carcinoembryonic Antigen Ratio and Response Evaluation

- Criteria in Solid Tumors as Prognostic Surrogate Indicators of Metastatic Colorectal Cancer Patients Treated with Chemotherapy. *Ann Surg Oncol* 2015;22:2262-8. doi:10.1245/s10434-014-4228-y
2. **Huang S-C**, Lin J-K, Jiang J-K, Lin T-C, Chen W-S, Yang S-H, Wang H-S, Lin C-C, Chang S-C. Carcinoembryonic Antigen Clearance Rate May Be a Prognostic Indicator for Metastatic Colorectal Cancer Patients Receiving Chemotherapy. *Int Surg* 2016;101:510-16. doi:10.9738/intsurg-d-16-00161.1
 3. **Huang S-C**, Lin J-K, Jiang J-K, Lin T-C, Chen W-S, Yang S-H, Tang R-P, Chiang J-M, Tsai W-S, Yeh C-Y. Prognosis of the Neuroendocrine Tumors of the Colon and Rectum with Lymph Node Metastasis after Surgical Treatment with or without Adjuvant Therapy. *中華民國大腸直腸外科醫學會雜誌* 2016;27:29-35. doi:10.6312/SCRSTW.2016.27(1).10417
 4. **黃聖捷** (2016) · 大腸直腸癌的腫瘤指標：癌胚抗原 · *臨床醫學月刊*，77 (6)，376-379。
 5. Tsai YJ, **Huang SC**, Lin HH, Lin CC, Lan YT, Wang HS, Yang SH, Jiang JK, Chen WS, Lin TC, Lin JK, Chang SC. Differences in gene mutations according to gender among patients with colorectal cancer. *World J Surg Oncol* 2018;16:128. doi:10.1186/s12957-018-1431-5
 6. Lin CC, **Huang SC**, Lin HH, Huang WJ, Chen WS, Yang SH. Naked-eye box trainer and training box games have similar training effect as conventional video-based box trainer for novices: A randomized controlled trial. *Am J Surg* 2018;216:1022-27. doi:10.1016/j.amjsurg.2018.05.015
 7. Ho SY, Chang BH, Chung CH, Lin YL, Chuang CH, Hsieh PJ, Huang WC, Tsai NM, **Huang SC**, Liu YK, Lo YC, Liao KW. Development of a computational promoter with highly efficient expression in tumors. *BMC Cancer* 2018;18:480. doi:10.1186/s12885-018-4421-7
 8. Teng HW, Lin JK, Lin TC, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, **Huang SC**. Planned Short-Course Radiation (scRT) is Superior to Upfront Concurrent Chemoradiation (CCRT) in Treating Metastatic Rectal Cancer. *J Gastrointest Surg* 2020;24:1092-100. doi:10.1007/s11605-019-04256-3
 9. Kuan TC, Chang SC, Lin JK, Lin TC, Yang SH, Jiang JK, Chen WS, Wang HS, Lan YT, Lin CC, Lin HH, **Huang SC**. Prognosticators of Long-Term Outcomes of TNM Stage II Colorectal Cancer: Molecular Patterns or Clinicopathological Features. *World J Surg* 2019;43:3207-15. doi:10.1007/s00268-019-05158-w
 10. Lin Y-Z, Liang W-Y, Lin H-H, Lin C-C, Jiang J-K, **Huang S-C**. Management of tailgut cysts in a single institute in Taiwan. *Formosan Journal of Surgery* 2019;52:11-16. doi:10.4103/fjs.fjs_61_18
 11. Tai CC, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, **Huang SC**, Cheng HH, Chao Y, Teng HW. Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer. *Am J Clin Oncol* 2020;43:28-34. doi:10.1097/coc.0000000000000637
 12. Chen TH, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, **Huang SC**, Cheng HH, Chau GY, Hsia CY, Lei HJ, Chou SC, Chao Y, Teng HW. Effect of Primary Tumor Location on Postmetastasectomy Survival in Patients with Colorectal Cancer Liver Metastasis. *J Gastrointest Surg* 2021;25:650-61. doi:10.1007/s11605-020-04855-5

13. Lin CC, **Huang SC**, Lin HH, Chang SC, Chen WS, Jiang JK. An early experience with the Senhance surgical robotic system in colorectal surgery: a single-institute study. *Int J Med Robot* 2021;17:e2206. doi:10.1002/rcs.2206
14. Yang YW, **Huang SC**, Chang SC, Wang HS, Yang SH, Chen WS, Lan YT, Lin CC, Lin HH, Jiang JK. Three-dimensional versus conventional two-dimensional laparoscopic colectomy for colon cancer: A 3-year follow-up study. *J Minim Access Surg* 2021. doi:10.4103/jmas.JMAS_31_21
15. Hsu HC, Huang KC, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, **Huang SC**, Cheng HH, Yang TS, Chen CC, Chao Y, Teng HW. Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread. *Sci Rep* 2021;11:15370. doi:10.1038/s41598-021-94968-x
16. Lan YT, Chang SC, Lin PC, Lin CC, Lin HH, **Huang SC**, Lin CH, Liang WY, Chen WS, Jiang JK, Lin JK, Yang SH. Clinicopathological and Molecular Features of Colorectal Cancer Patients With Mucinous and Non-Mucinous Adenocarcinoma. *Front Oncol* 2021;11:620146. doi:10.3389/fonc.2021.620146
17. Lan YT, Chang SC, Lin PC, Lin CC, Lin HH, **Huang SC**, Lin CH, Liang WY, Chen WS, Jiang JK, Yang SH, Lin JK. Clinicopathological and molecular features between synchronous and metachronous metastases in colorectal cancer. *Am J Cancer Res* 2021;11:1646-58
18. Lan YT, Chang SC, Lin PC, Lin CC, Lin HH, **Huang SC**, Lin CH, Liang WY, Chen WS, Jiang JK, Yang SH, Lin JK. Clinicopathological and Molecular Features of Patients with Early and Late Recurrence after Curative Surgery for Colorectal Cancer. *Cancers (Basel)* 2021;13. doi:10.3390/cancers13081883
19. Lee KH, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, **Huang SC**, Cheng HH, Chao Y, Teng HW. The efficacy of anti-EGFR therapy in treating metastatic colorectal cancer differs between the middle/low rectum and the left-sided colon. *Br J Cancer* 2021;125:816-25. doi:10.1038/s41416-021-01470-2
20. **Huang SC**, Lin CC, Teng HW, Lin HH, Chang SC, Lan YT, Wang HS, Yang SH, Chen WS, Jiang JK. A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer. *Front Oncol* 2022;12:808808. doi:10.3389/fonc.2022.808808
21. Su, YT., Chen, JW., Chang, SC. **Huang SC**. The clinical experience of the prognosis in opposite CEA and image change after therapy in stage IV colorectal cancer. *Sci Rep* 12, 20075 (2022). <https://doi.org/10.1038/s41598-022-24187-5>
22. **Huang SC**, Chang SC, Liao TT, Yang MH. Detection and clinical significance of CEACAM5 methylation in colorectal cancer patients. *Cancer Sci.* 2024 Jan;115(1):270-282. doi: 10.1111/cas.16012. Epub 2023 Nov 9. PMID: 37942534; PMCID: PMC10823287.
23. Kao YC, Yang MY, Chen WS, Jiang JK, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, **Huang SC**, Cheng HH, Lin YZ, Yang YW, Teng HW. The salvage lenvatinib-based regimen provides survival benefit in patients with refractory metastatic colorectal cancer. *Am J Cancer Res.* 2024 May 15;14(5):2187-2201. doi: 10.62347/YKZB8359. PMID: 38859851; PMCID: PMC11162670.
24. Yang JH, Lin WL, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, **Huang SC**, Cheng HH, Yang YW, Lin YZ, Hsu HM, Lin CJ, Teng HW. The

survival outcome differs between left-sided colon cancer and middle/low rectal cancer after colorectal hepatic metastasectomy. *J Gastrointest Surg.* 2024 Aug;28(8):1250-1258. doi: 10.1016/j.gassur.2024.05.020. Epub 2024 May 21. PMID: 38782088.

25. Tseng KY, Yang MY, Chen WS, Jiang JK, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, **Huang SC**, Cheng HH, Yang YW, Lin YZ, Chang CY, Teng HW. Combining moderate dosage of Bevacizumab with TAS-102 provides longer progression-free time in refractory metastatic colorectal Cancer. *Int J Colorectal Dis.* 2024 Dec 4;39(1):195. doi: 10.1007/s00384-024-04767-9. PMID: 39630293; PMCID: PMC11618181.

Curriculum Vitae

Name : Kuan, Feng-Che (官鋒澤)

Sex: Male

Citizenship: Taiwan, Republic of China

Office Address: No. 6, W. Sec., Jiapu Rd., Puzih City, Chiayi County 61363, Taiwan (R.O.C)

Phone: +886-5-362100 ext. 2852

Language: Chinese, English

Email : mnpq8893@gmail.com; 8902029@cgmh.org.tw

Education:

2000-2007, Chang-Gung University, School of Medicine, Taoyuan, Taiwan

Post-Graduate Education :

2007-2010, Residentsip, Department of Internal Medicine, Chang Gung Memorial Hospital, Chia-Yi, Taiwan

2010-2012, Fellowship, Department of Hematology and Oncology, Chang Gung Memorial Hospital, Chia-Yi, Taiwan

Academic Appointment (Include Teaching Experience):

2010-2011, Medicine Chief Executive, MD, Department of Internal Medicine, Chang Gung Memorial Hospital, Chia-Yi, Taiwan

2015/1/1-2015/12/31, Medical Consultant in Colorectal Cancer Committee, National Health Research Institutes, Taiwan

Employment Record :

2007-2010, Residentsip, Department of Internal Medicine, Chang Gung Memorial Hospital, Chia-Yi, Taiwan

2010-2012, Fellowship, Department of Hematology and Oncology, Chang Gung Memorial Hospital, Chia-Yi, Taiwan

2012-til now, Visiting Staff, Department of Hematology and Oncology, Chang Gung Memorial Hospital, Chia-Yi, Taiwan

Board-certified specialist:

Board of Internal Medicine (License NO: 008889)

Board of Medical Oncology (License NO: 101021)

Professional Affiliations:

Member, Taiwan Society of Internal Medicine

Member, The Chinese Oncology Society

Member, American Society of Clinical Oncology (No. 6914979)

Review Service:

2024-present Journal of Thoracic Oncology

Research Interest:

1. Gastrointestinal malignancies
2. Lung cancer
3. Breast cancer
4. Cancer of unknown primary
5. Cancer therapeutics

International/Taiwan collaborations:

1. Hill W, Lim EL, Weeden CE, Lee C, Augustine M, Chen K, **Kuan FC**, Marongiu F, Evans EJ Jr, Moore DA, Rodrigues FS, Pich O, Bakker B, Cha H, Myers R, van Maldegem F, Boumelha J, Veeriah S, Rowan A, Naceur-Lombardelli C, Karasaki T, Sivakumar M, De S, Caswell DR, Nagano A, Black JRM, Martínez-Ruiz C, Ryu MH, Huff RD, Li S, Favé MJ, Magness A, Suárez-Bonnet A, Priestnall SL, Lüchtenborg M, Lavelle K, Pethick J, Hardy S, McDonald FE, Lin MH, Troccoli CI, Ghosh M, Miller YE, Merrick DT, Keith RL, Al Bakir M, Bailey C, Hill MS, Saal LH, Chen Y, George AM, Abbosh C, Kanu N, Lee SH, McGranahan N, Berg CD, Sasieni P, Houlston R, Turnbull C, Lam S, Awadalla P, Grönroos E, Downward J, Jacks T, Carlsten C, Malanchi I, Hackshaw A, Litchfield K; TRACERx Consortium; DeGregori J, Jamal-Hanjani M, Swanton C. Lung adenocarcinoma promotion by air pollutants. *Nature*. 2023 Apr;616(7955):159-167. doi: 10.1038/s41586-023-05874-3. Epub 2023 Apr 5. PMID: 37020004. (SCI: 69.5)
2. Yeh KH, Yang TS, Hsu TC, Tzu-Liang Chen W, Chen HH, Teng HW, Lin BW, **Kuan FC**, Chiang FF, Duann CW, Li YS, Lin MT, Fiala-Buskies S, Ducreux M, Wang JY. Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan. *J Formos Med Assoc*. 2021 Nov;120(11):2023-2031. doi: 10.1016/j.jfma.2020.12.015. Epub 2021 Jan 7. PMID: 33422398. (SCI: 3.87)
3. Loupakis F, Antonuzzo L, Bachet JB, **Kuan FC**, Macarulla T, Pietrantonio F, Xu RH, Taniguchi H, Winder T, Yuki S, Zeng S, Bekaii-Saab T. Practical considerations in the use of regorafenib in metastatic colorectal cancer. *Ther Adv Med Oncol*. 2020 Oct 31;12:1758835920956862. doi: 10.1177/1758835920956862. PMID: 33193826; PMCID: PMC7607787. (SCI: 5.48)

Journal Publications:

1. **Kuan FC**, Li JM, Huang YC, Chang SF, Shi CS. Therapeutic Potential of Regorafenib in Cisplatin-Resistant Bladder Cancer with High Epithelial-Mesenchymal Transition and Stemness Properties. *Int J Mol Sci*. 2023 Dec 18;24(24):17610. doi: 10.3390/ijms242417610 (SCI: 5.6)
2. Yang YR, Shi CC, Chang SW, Wu YY, Su YL, Lin GP, **Kuan FC***. The impact of sarcopenia on overall survival in patients with pan-RAS wild-type colorectal liver metastases receiving hepatectomy. *Sci Rep* 2023 Apr 27; 13 (1): 6911; doi: 10.1038/s41598-023-33439-x (SCI: 4.997)

3. **Kuan FC**, Lee KD, Huang SF, Chen PT, Huang CE, Wang TY, Chen MC*. Radiotherapy is associated with an accelerated risk of ischemic stroke in oral cavity cancer survivors after primary surgery. *Cancers*. Mar 6, 2020; doi: 10.3390/cancers12030616 (SCI: 6.126)
4. Huang WS, **Kuan FC**, Lin MH, Chen MF, Chen WC*. Prognostic significance of neoadjuvant rectal scores in preoperative short-course radiotherapy and long-course concurrent chemoradiotherapy for patients with locally advanced rectal cancer. *Ann Surg Oncol*. Oct, 2020; doi: 10.1245/s10434-020-09018-z (SCI: 4.061)
5. Chen MC, **Kuan FC**, Huang SF, Lu CH, Che PT, Huang CE, Wang TY, Chen CC, Lee KD*. Accelerated risk of premature ischemic stroke in 5-year survivors of nasopharyngeal carcinoma. *Oncologist*. Sep 2019; doi: 10.1634/theoncologist.2018-0747 (SCI: 5.025)
6. **Kuan FC**, Lai CH, Ku HY, Wu CF, Hsieh MC, Liu TW, Yeh CY, Lee KD*. The survival impact of delayed surgery and adjuvant chemotherapy on stage II/III rectal cancer with pathological complete response after neoadjuvant chemoradiation. *Int J Cancer*. Apr 1, 2017; doi: 10.1002/ijc.30562 (SCI: 5.145)
7. Hsieh MC, Wu CF, Chen CW, Shi CC, Huang WS, **Kuan FC***. Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis. *Sci Rep*. Feb 1, 2018; doi: 10.1038/s41598-018-19835-8 (SCI: 3.998)
8. **Kuan FC**, Li SH, Wang CL, Lin MH, Tsai YH, Yang CT*. Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small-cell lung cancer harboring leu858Arg or exon 19 deletions. *Oncotarget*. Dec 7, 2016; doi: 10.18632/oncotarget.13815 (SCI: 5.168 [2016])
9. **Kuan FC**, Kuo LT, Chen MC, Yang CT, Shi CS, Teng David, Lee KD*. Overall survival benefits of first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutated non-small-cell lung cancers (NSCLCs): A systematic review and meta-analysis. *Br J Cancer*. Nov 17, 2015; doi: 10.1038/bjc.2015.356 (SCI: 5.416)
10. Chen PT, **Kuan FC**, Huang CE, Chen MF, Huang SH, Chen MC, Lee KD*. Incidence and Patterns of Second Primary Malignancies Following Oral Cavity Cancers in a Prevalent Area of Betel-nut Chewing: A Population-based Cohort of 26166 Patients in Taiwan. *Jpn J Clin Oncol*. Oct 24, 2011; doi:10.1093/jjco/hyr152 (SCI: 1.914)
11. **Kuan FC**, Lin PY, Hwang CE, Lu CH and Chen CC*. Letter to the editor: Pancytopenia and myeloid maturation arrest in an autologous stem cell transplant recipient. *Bone Marrow Transplantation* July 12, 2010; doi:10.1038/bmt.2010.155 (SCI: 4.725)
12. Chen MF, **Kuan FC**, Yen TC, Lu MS, Lin PY, Chung YH, Chen WC, Lee KD. IL-6-stimulated CD11b+HLA-DR-myeloid-derived suppressor cells are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus. *Oncotarget* 2014; 5(18): 8716-8728 (SCI: 6.359)
13. Lu CH, Lee KD, Chen PT, Chen CC, **Kuan FC**, Huang CE, Chen MF, Chen MC. Second primary malignancies following thyroid cancer: a population-based study in Taiwan. *Eur J Endocrinol* 2013;169:577-85. (SCI: 5.308)
14. **Kuan FC**, Hsieh CC, Lee KF, Chen PT, Chen CC, Lee KD, Lu CH*. Pseudomyxoma peritonei mimicking acute appendicitis and peritonitis. *J Cancer Res Pract* 2012;28(4):170-176.

15. Wang TY, Lee KD, Chen PT, Chen MC, Chen YY, Huang CE, **Kuan FC**, Chen CC, Lu CH. Incidence and risk factors for central venous access port-related infection in Chinese cancer patients. J Formos Med Assoc. 2015 Aug 4. pii: S0929-6646(15)00236-3 (SCI:3.008)
16. Huang CE, Lu CH, Chen PT, Chan CH, Chen WC, Wang WH, Wu JY, **Kuan FC**, Lee KD, Chen CC. Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer. J Clin Pharm Ther. 2012 Jun;37(3):342-7 (SCI: 2.028)

Meeting abstracts:

1. Kuan FC, Lin GP, Chiu WN, Chen CJ, Chin CC, Huang WS, Fan CW, Chiang JM, Chen HW, Chen JS, Lee KD. Dissecting the prognostic role of sidedness in metastatic colon cancer (mCC): retrospective analysis of the impact of chemotherapy sequence (CTS) and primary site resection (PTR) in a health care system. Journal of Clinical Oncology 36, no. 15_suppl - published online before print. DOI: 10.1200/JCO.2018.36.15_suppl.e15502
2. Kuan FC, Kuo LT, Yang WH, Shi CC, Chen MC, Chang WC, Yang CT, Lee KD. Dissecting the prognostic role of common EGFR-mutations of metastatic NSCLC in TKI era: a systematic review and subgroup meta-analysis. Journal of Clinical Oncology 36, no. 15_suppl (May 2018) 9079-9079. DOI: 10.1200/JCO.2018.36.15_suppl.9079
3. Kuan FC, Yang WH, Lai HY, Huang CC, Yang CT, Shi CS. Real-world outcome analysis of EGFR-mutated lung adenocarcinoma with brain metastases. Journal of Clinical Oncology 37, no. 15_suppl (May 2019) e13588. DOI: 10.1200/JCO.2019.37.15_suppl.e13588
4. Kuan FC, Kuo LT, Hsieh MC, Chen MC, Lee KD. Add-on anti-vascular endothelial growth factor agents with the second-line chemotherapy in metastatic colorectal cancer: a metastases of randomized trials. Journal of Clinical Oncology 37, no. 15_suppl (May 2019) e15059. DOI: 10.1200/JCO.2019.37.15_suppl.e15059
5. Kuan FC, Shi CS, Yang WH, Lai HY, Huang CC, Yang CT. Real-world evidence: molecular subtype and its prognostic implications of Lung-molGPA in EGFR-mutated adenocarcinoma. J Clin Oncol 38: 2020 (suppl; abstr e21621)
6. Kuan FC, Lin GP, Chin CC, Huang WS, Fan CW, Chiang JM, Chen HW, Chen JS. Real-world evidence: adjuvant chemotherapy in colorectal cancer with liver metastases. J Clin Oncol 38: 2020 (suppl; abstr e16008)
7. Kuan FC, Shi CS, Wu YY, Lin MH. Braf-altered microsatellite-stable metastatic colorectal cancer: A niche for immunotherapy. Proceedings of the AACR Apr 2022; 61: abs 5212
8. Kuan FC, Shi CS, Lin MH. Correlation of BRAF genomic alterations with higher mutation burden and predictive response to immune checkpoint inhibitors among human malignancies. J Clin Oncol 40: 2022 (suppl; abstr e14589)
9. Kuan FC, Yang YR, Wu YY, Lin MH, Shi CS. Prognostic factors and long-term survivors in EGFR-mutated lung cancer: a multi-institutional retrospective analysis. J Clin Oncol 42: 2024 (suppl; abstr e20594)

Signature:

Date:

CURRICULUM VITAE

CONTACT INFORMATION

Name: Lin, Chang-Lin
Telephone: (O) +886-4-23592525-5161
Cell Phone: +886-935-831919
Email: opzimbardo@gmail.com



PERSONAL INFORMATION

Date of Birth: Dec. 23, 1987
Place of Birth: Taiwan

Education

Sep 2006 – Jun 2013 Chung Shan Medical University, Taiwan

Career

台中榮總外科部 住院醫師
台中榮總直腸外科 總醫師
台中榮總埔里分院 主治醫師
台中榮總直腸外科 主治醫師

Board certification

OCT 2013	Medical License Examination, Republic of China, Taiwan
DEC 2019	Surgery Board Examination, Taiwan
DEC 2020	Member of Society of Colon and Rectal Surgeons, Taiwan

SCI paper

Tattooing or Metallic Clip Placement? A Review of the Outcome Surrounding Preoperative Localization Methods in Minimally Invasive Anterior Resection Performed at a Single Center. Surgical Laparoscopy Endoscopy & Percutaneous Techniques 32(1):p 101-106, 2022.

Curriculum Vitae

Personal Information:

Name: Chun-Kai Liao, MD

Office Address: Division of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital, Linkou, No. 5, Fuxing St., Guishan Dist., Taoyuan, 333423, Taiwan.

TEL: 886-3-328-1200 Ext. 2101

Language: Taiwanese, Chinese, and English

Education:

Jul 2003 – Jun 2010: MD, China Medical University, Taichung, Taiwan

Post-graduate Education/Fellowship:

1. Jun 2009 – May 2010: Internship, China Medical University Hospital, Taichung, Taiwan
2. Oct 2011 – Sep 2012: Resident, General Surgery, Chang Gung Memorial Hospital, ChiaYi, Taiwan
3. Oct 2012 – Sep 2015: Resident, General Surgery, Chang Gung Memorial Hospital, Linkou, Taiwan
4. Oct 2015 – Sep 2017: Resident, Division of Colon and Rectal Surgery, Chang Gung Memorial Hospital, Linkou, Taiwan
5. Oct 2017 – Sep 2018: Fellowship, Division of Colon and Rectal Surgery, Chang Gung Memorial Hospital, Linkou, Taiwan
6. Mar 1-30 2019: Visiting fellow, Division of ColoRectal Surgery, Yokohama City University Medical Center, Japan

Academic Appointments

1. Oct 2018 – Jun 2020: Attending Physician, Division of Colon and Rectal Surgery, Chang Gung Memorial Hospital, Linkou, Taiwan
2. Jul 2020 – Jun 2022: Clinical Instructor, Division of Colon and Rectal Surgery, Chang Gung Memorial Hospital, Linkou, Taiwan
3. Jul 2022 – Present: Assistant Professor, Division of Colon and Rectal Surgery, Chang Gung Memorial Hospital, Linkou, Taiwan
4. Feb 2024 – Present: Assistant Professor, School of Medicine, Chang Gung University, Taiwan

Affiliation with Medical organization:

1. Taiwan Surgical Association member ID: 2-6381
2. Society of Colon and Rectal Surgeons, Taiwan member ID: 426
3. Taiwan oncology society member ID: 01701

Publications:

1. Hsu JT, **Liao CK**, Le PH, et al. Prognostic Value of the Preoperative Neutrophil to Lymphocyte Ratio in Resectable Gastric Cancer. *Medicine (Baltimore)*. 2015;94(39):e1589. (SCI; IF=1.3; Medicine 143/325 Q2)
2. **CK Liao**, CY Yeh, YM Tseng, et al. Neoadjuvant Long Course CCRT Significantly Increases Disease Free Survival among Pathological Stage III Rectal Cancer Patients as Compared to Short Course RT Alone. *J Soc Colon Rectal Surgeon (Taiwan)*. 2017;28(1):18-26.
3. **Liao C-K**, Chiang J-M, Tsai W-S, et al. Primary tumor location in stage III colon cancer has prognostic impact on subsequent liver metastasis. *J Surg Oncol*. 2018;118:1301-1310. (SCI; IF=2.0; Surgery 108/290 Q2)
4. **Liao, CK.**, Chern, YJ., Lin, YC. et al. Short- and medium-term outcomes of intracorporeal versus extracorporeal anastomosis in laparoscopic right colectomy: a propensity score-matched study. *World J Surg Onc* 19, 6 (2021). (SCI; IF=2.5; Surgery 68/290 Q1)
5. Cheng, CC., Hsu, YR., **Liao, CK.** et al. Minimally invasive right colectomy with transrectal natural orifice extraction: could this be the next step forward?. *Tech Coloproctol* 24, 1197–1205 (2020).(SCI; IF=2.7; Surgery 56/290 Q1)
6. Huang SH, Wu RC, **Liao CK***, et al. An uncommon form of localized colonic eosinophilic vasculitis with extensive thrombosis of the spleen and liver: A case report and literature review. *Int J Surg Case Rep*. 2020;75:50-52.
7. Kuo YT, Chern YJ, **Liao CK*** et al. Short-course Radiation Therapy Followed by Chemotherapy as Preoperative Treatment for Rectal Cancer. *J Soc Colon Rectal Surgeon (Taiwan)*. 2021;32:7-16
8. **Liao, CK.**, Yu, YL., Lin, YC. et al. Prognostic value of the C-reactive protein to albumin ratio in colorectal cancer: an updated systematic review and meta-analysis. *World J Surg Onc* 19, 139 (2021). (SCI; IF=2.5; Surgery 68/290 Q1)
9. **Liao CK**, Lin YC, Hsu YJ, Chern YJ, You JF, Chiang JM. Deciding the operation type according to mismatch repair status among hereditary nonpolyposis colorectal cancer patients: should a tailored approach be applied, or does one size fit all? *Hered Cancer Clin Pract*. 2021 Jun 29;19(1):29. (SCI; IF=2.0; Oncology 221/322 Q3)
10. **Liao C-K**, Chern Y-J, Hsu Y-J, Lin Y-C, Yu Y-L, Chiang J-M, Yeh C-Y, You J-F. The Clinical Utility of the Geriatric Nutritional Risk Index in Predicting Postoperative

Complications and Long-Term Survival in Elderly Patients with Colorectal Cancer after Curative Surgery. *Cancers*. 2021; 13(22):5852. (SCI; IF=4.5; Oncology 91/322 Q2)

11. Jong BK, Cheng CC, Hsu YJ, Chern YJ, Tsai WS, Hung HY, **Liao CK**, Yeh CY, Hsieh PS, You JF. Transrectal natural orifice specimen extraction in left hemicolectomy for tumours around the splenic flexure: Old wine in new bottles. *Colorectal Dis*. 2022 Jan;24(1):128-132. (SCI; IF=2.9; Surgery 49/290 Q1)
12. Kuo YT, **Liao CK**, Chen TC, Lai CC, Chiang SF, Chiang JM. A high density of PD-L1-expressing immune cells is significantly correlated with favorable disease free survival in nonmetastatic colorectal cancer. *Medicine (Baltimore)*. 2022;101(3):e28573. (SCI; IF=1.3; Medicine 143/325 Q2)
13. Tsai, K. Y., Tsai, W. S., Huang, S. H., Lai, I. L., Sun, C. Y., Cheng, C. C., **Liao, C. K.**, Lin, Y. C., Chern, Y. J., Hsu, Y. J., Lin, G. P., Lai, C. C., Chiang, S. F., You, J. F., Hung, H. Y., Yeh, C. Y., Hsieh, P. S., Chiang, J. M., Tang, R. P., & Chen, J. S. (2021). Surgical Outcome of Stoma Closure in IBD Surgery. *J Soc Colon Rectal Surgeon (Taiwan)*.32(3), 105-113.
14. Wang, L. M., You, J. F., Huang, S. H., Lai, I. L., Sun, C. Y., Cheng, C. C., **Liao, C. K.**, Lin, Y. C., Chern, Y. J., Hsu, Y. J., Lin, G. P., Lai, C. C., Chiang, S. F., Tsai, W. S., Hung, H. Y., Yeh, C. Y., Hsieh, P. S., Chiang, J. M., Tang, R. P., & Chen, J. S. (2021). Postoperative Follow-up Strategies for the Detection of Recurrence in Patients with Early-stage Colorectal Cancer. *J Soc Colon Rectal Surgeon (Taiwan)*. 32(4), 182-190.
15. Chern, Y.-J.; You, J.-F.; Cheng, C.-C.; Jhuang, J.-R.; Yeh, C.-Y.; Hsieh, P.-S.; Tsai, W.-S.; **Liao, C.-K.**; Hsu, Y.-J. Decreasing Postoperative Pulmonary Complication Following Laparoscopic Surgery in Elderly Individuals with Colorectal Cancer: A Competing Risk Analysis in a Propensity Score–Weighted Cohort Study. *Cancers* 2022, 14, 131. (SCI; IF=4.5; Oncology 91/322 Q2)
16. **Liao, C.-K.**; Kuo, Y.-T.; Lin, Y.-C.; Chern, Y.-J.; Hsu, Y.-J.; Yu, Y.-L.; Chiang, J.-M.; Hsieh, P.-S.; Yeh, C.-Y.; You, J.-F. Neoadjuvant Short-Course Radiotherapy Followed by Consolidation Chemotherapy before Surgery for Treating Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis. *Curr. Oncol.* 2022, 29, 3708-3727. (SCI; IF=2.8; Oncology 157/322 Q2)
17. **Liao, C.-K.**; Kuo, Y.-T.; Chern, Y.-J.; Hsu, Y.-J.; Lin, Y.-C.; Yu, Y.-L.; Hsieh, P.-S.; Chiang, J.-M.; Yeh, C.-Y.; You, J.-F. Tegafur–Uracil/Leucovorin Plus Oxaliplatin (TEGAFOX) as Consolidation Regimen after Short-Course Radiotherapy Is Effective for Locally

Advanced Rectal Cancer. J. Clin. Med. 2022, 11, 2920. (SCI; IF=3.0; Medicine 58/325 Q1)

18. Lin, Y.-C.; Kuo, Y.-T.; You, J.-F.; Chern, Y.-J.; Hsu, Y.-J.; Yu, Y.-L.; Chiang, J.-M.; Yeh, C.-Y.; Hsieh, P.-S.; **Liao, C.-K***. Transanal Total Mesorectal Excision (TaTME) versus Laparoscopic Total Mesorectal Excision for Lower Rectal Cancer: A Propensity Score-Matched Analysis. Cancers 2022, 14, 4098. (SCI; IF=4.5; Oncology 91/322 Q2)
19. Wang, LM., Jong, BK., **Liao, CK**. et al. Comparison of short-term and medium-term outcomes between intracorporeal anastomosis and extracorporeal anastomosis for laparoscopic left hemicolectomy. World J Surg Onc 20, 270 (2022). (SCI; IF=2.5; Surgery 68/290 Q1)
20. Hsu YJ, Chern YJ, Lai IL, Chiang SF, **Liao CK**, Tsai WS, Hung HY, Hsieh PS, Yeh CY, Chiang JM, Yu YL, You JF. Usefulness of close surveillance for rectal cancer patients after neoadjuvant chemoradiotherapy. Open Med (Wars). 2022 Sep 5;17(1):1438-1448 (SCI; IF=1.7; Medicine 116/325 Q2)
21. You JF, Hsu YJ, Chern YJ, Cheng CC, Jong BK, **Liao CK**, Hsieh PS, Hsu HC, Tsai WS. Preoperative Cancer Inflammation Prognostic Index as a Superior Predictor of Short- and Long-Term Outcomes in Patients with Stage I-III Colorectal Cancer after Curative Surgery. Cancers (Basel). 2022 Dec 17;14(24):6232. doi: 10.3390/cancers14246232.(SCI; IF=4.5; Oncology 91/322 Q2)
22. Yu YL, Hsu YJ, **Liao CK**, Lin YC, You JF, Tsai WS, Jong BK, Chern YJ. Advantage of laparoscopic surgery in patients with generalized obesity operated for colorectal malignancy: A retrospective cohort study. Front Surg. 2023 Jan 6;9:1062746. doi: 10.3389/fsurg.2022.1062746. (SCI; IF=1.6; Surgery 144/290 Q2)
23. Hsu, CC., Hsu, YJ., Chern, YJ., **Liao CK**. et al. Potential short-term outcome advantage of low vs. high ligation of inferior mesenteric artery for sigmoid and rectal cancer: propensity score matching analysis. BMC Surg 23, 33 (2023). <https://doi.org/10.1186/s12893-023-01932-9> (SCI; IF=1.6; Surgery 144/290 Q2)
24. Chiang T-Y, Hsu H-C, Chern Y-J, **Liao C-K**, Hsu Y-J, Tsai W-S, Hsieh P-S, Lin Y-F, Lee H-L, You J-F. Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy? Cancers. 2023; 15(6):1663. <https://doi.org/10.3390/cancers15061663> (SCI; IF=4.5; Oncology 91/322 Q2)

25. **Liao, CK**, Kuo, YT., Hsu, YJ. et al. Effect of short-course radiotherapy followed by oxaliplatin-based consolidation chemotherapy on organ preservation in locally advanced rectal cancer. *Int J Colorectal Dis* 38, 92 (2023). <https://doi.org/10.1007/s00384-023-04388-8> (SCI; IF=2.5; Surgery 68/290 Q1)
26. Tsai T-Y, **Liao C-K**, Zhang B-Y, Huang Y-L, Tsai W-S, You J-F, Yeh C-Y, Hsieh P-S. Perianal Basal Cell Carcinoma—A Systematic Review and Meta-Analysis of Real-World Data. *Diagnostics*. 2023; 13(9):1650. <https://doi.org/10.3390/diagnostics13091650> (SCI; IF=3.0; Medicine 58/325 Q1)
27. Lo, SJ., Huang, SH., Lai, IL., **Liao, CK**. et al. Upfront primary tumor resection versus upfront systemic therapy for metastatic colorectal cancer: a systematic review and meta-analysis. *Int J Colorectal Dis* 38, 186 (2023). <https://doi.org/10.1007/s00384-023-04483-w> (SCI; IF=2.5; Surgery 68/290 Q1)
28. Chern YJ, Hsu HY, Hsu YJ, Hsu LY, Tsai WS, **Liao CK**, Jong BK, You JF. Tumor Marker Trajectories and Survival Analysis in Patients with Normal Carcinoembryonic Antigen Ranges After Colorectal Cancer Resection. *Dis Colon Rectum*. 2023 Aug 15. doi: 10.1097/DCR.0000000000002894. (SCI; IF=3.2; Surgery 41/290 Q1)
29. Yu, YL., Tseng, WK., **Liao, CK**. et al. Using oral tegafur/uracil (UFT) plus leucovorin as adjuvant chemotherapy in stage II colorectal cancer: a propensity score matching study from Taiwan. *BMC Cancer* 23, 900 (2023). <https://doi.org/10.1186/s12885-023-11310-6> (SCI; IF=3.4; Oncology 110/322 Q2)
30. Hsu Y-J, Chern Y-J, Wu Z-E, Yu Y-L, **Liao C-K**, Tsai W-S, et al. The oncological outcome and prognostic factors for Solitary Colorectal Liver Metastasis after liver resection. *J Gastrointest Surg*. 2024. <https://doi.org/10.1016/j.gassur.2024.01.003>. (SCI; IF=2.2; Surgery 96/290 Q2)
31. Chiang TY, Hsu YJ, Chern YJ, **Liao CK**, Tsai WS, Hsieh PS, Hsu HC, Lin YF, Lee HL, You JF. Association between personality types and low anterior resection syndrome in rectal cancer patients following surgery. *Cancer Med*. 2024 Feb;13(3):e7022. doi: 10.1002/cam4.7022. PMID: 38400678; PMCID: PMC10891461. (SCI; IF=2.9; Oncology 151/322 Q2)
32. Hsu YJ, Yu YL, Jhuang JR, You JF, **Liao CK**, Tsai WS, Pan YP, Chern YJ. Comparison of laparoscopic and open surgery for colorectal malignancy in obese patients: a propensity score-weighted cohort study. *Int J Surg*. 110(8):p 4598-4607, August 2024. doi: 10.1097/JS9.0000000000001536. Epub ahead of print. PMID: 38833348. (SCI; IF=12.5; Surgery 2/290 Q1)

33. Chia-Chen Hsu 、Ya-Tin Kuo 、Yueh-Chen Lin 、**Chun-Kai Liao** 、Yu-Jen Hsu 、Jy-Ming Chiang (2024) .Risk of Colorectal and Gynecologic Cancer in Varied Degree Relatives of Lynch Syndrome and Lynch-like Syndrome Families. J Soc Colon Rectal Surgeon (Taiwan).35(3) , 121-131
34. Chan, LY., Chern, YJ., Hsu, YJ., **Liao CK.** et al. Short-term outcomes of Transrectal Natural Orifice Specimen extraction compared with conventional minimally invasive surgery for selected patients with colorectal cancer: a propensity score matching analysis and literature review. World J Surg Onc 22, 237 (2024). <https://doi.org/10.1186/s12957-024-03513-3> (SCI; IF=2.5; Surgery 68/290 Q1)
35. **Liao C-K**, Hsu Y-J, Chern Y-J, Yu Y-L, Lin Y-C, Hsieh P-S, et al. Differences in characteristics and outcomes between early-onset colorectal cancer and late-onset colorectal cancers. Eur J Surg Oncol. 2024;108687. (SCI; IF=3.5; Surgery 31/292 Q1)
36. Chern, YJ., Hsu, YJ., Hsu, HY., **Liao, CK.** et al. Domains of four-step technique training program for laparoscopic colorectal surgery. Tech Coloproctol 28, 156 (2024). <https://doi.org/10.1007/s10151-024-03042-x> (SCI; IF=2.7; Surgery 56/292 Q1)



張伸吉 醫師

Jeffrey, Sheng-Chi Chang, M.D PhD

■ 介紹

張伸吉醫師師承陳自諒教授，精熟各式大腸直腸微創手術後，再遠赴荷蘭 Catharina Ziekenhuis 醫院進行腹膜腫瘤手術暨熱化療進修，並於 2019 年至新加坡 National University 醫院取得「加壓腹膜內氣霧化學療法(PIPAC)」完訓證明。張醫師為人和藹可親，手術經驗豐富，解說詳細，在微創手術上的研究更是首屈一指，尤其專精「大腸直腸癌」及「腹膜惡性腫瘤」的治療，目前也擔任這兩個科室的負責人。

■ 專長

1. 各式大腸直腸癌微創手術
2. 腹膜腫瘤特殊治療 [腹腔熱化療(HIPEC)、加壓腹膜內氣霧化學療法(PIPAC)]
3. 各式微創痔瘡手術；微創肛門瘻管手術 (雷射瘻管消融)
4. 大腸直腸癌 細胞免疫治療

■ 現職

中國醫藥大學附設醫院 大腸直腸外科主任

中國醫藥大學附設醫院 腹膜腫瘤治療中心主任

中國醫藥大學附設醫院 細胞治療中心副主任

大腸直腸癌團隊副負責人

台灣腹膜腫瘤醫學會理事 及 中華民國傷口醫學會理事

■ 學歷

中國醫藥大學 醫學系醫學士

中國醫藥大學 醫學研究所碩士

中興大學 生命科學系 博士

■ 經歷

中國醫藥大學附設醫院 大腸直腸外科 主治醫師

中國醫藥大學附設醫院 外科總醫師

荷蘭 Catharina Ziekenhuis 醫院外科研究員

■ 研究

微創自然孔手術於大腸直腸癌上的臨床應用

腹腔熱化療於大腸直腸癌的應用與療效

細胞治療於結直腸癌的運用

■ 發表論文

1. **Chang SC**, et al. Short and long-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal and appendiceal cancer peritoneal metastasis: Propensity score-matched comparison between laparoscopy vs. open approaches. *Surg Oncol* 2022
2. **Chang SC**, et al. Peritoneal contamination and associated post-operative infectious complications after natural orifice specimen extraction for laparoscopic colorectal surgery. *Surg Endosc* 2022
3. **Chang SC**, et al. Laparoscopic total pelvic peritonectomy for colorectal cancer pelvic carcinomatosis: a retrospective case series and photographic/videographic step-by-step guide. *Surg Endosc* 2021
4. **Chang SC**, et al. Natural orifice versus conventional mini-laparotomy for specimen extraction after reduced-port laparoscopic surgery for colorectal cancer: propensity score-matched comparative study. *Surg Endosc* 2021
5. **Chang SC**, et al. Long-term Oncologic Outcomes of Laparoscopic Anterior Resections for Cancer with Natural Orifice versus Conventional Specimen Extraction: A Case-Control Study. *Dis Colon Rectum* 2020

6. Seow-En I, **Chang SC**, et al. Uncomplicated Sigmoid Volvulus Is Ideal for Laparoscopic Sigmoidectomy With Transrectal Natural Orifice Specimen Extraction. *Dis Colon Rectum* 2020
7. Saurabh B, **Chang SC**, et al. Natural orifice specimen extraction with single stapling colorectal anastomosis for laparoscopic anterior resection: feasibility, outcomes, and technical considerations. *Dis Colon Rectum* 2017
8. **Chang SC**, et al. Laparoscopic Excision is an Alternative Method for Rectal Gastrointestinal Stromal Tumor. *Surg Laparosc Endosc Percutan Tech* 2010
9. **Chang SC**, et al. Experimental Study on Effect of Compounds in Inhibiting HCT-116 Human Colon Cancer Cell: the Preliminary Results. *J Soc Colon Rectal Surgeon (Taiwan)* 2010
10. **Chang SC**, Chen HH et al. Pleomorphic Liposarcoma of the Scalp: a case report and literature review. *J Plast Surg AssoR.O.C* 2008; 17: 198-204
11. Chen WT, **Chang SC**, et al. Single-incision Laparoscopic versus Conventional Laparoscopic Right Hemicolectomy: A Comparison of Short-Term Surgical Results. *Surgical Endoscopy* 2011
12. Chen WT, **Chang SC** et al. Identification of biomarkers to improve diagnostic sensitivity of sporadic colorectal cancer in patients with low preoperative serum carcinoembryonic antigen by clinical proteomic analysis. *Clin Chim Acta*. 2011
13. Seow-En I, Ke TW, **Chang SC** et al. Laparoscopic retrojejunal trans-mesenteric anastomosis for extended left-sided colorectal resections - a new solution to an old problem. *Colorectal Dis*. 2021
14. Chien A, Yang CC, **Chang SC** et al. Ultrasound Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Patients With Colorectal Cancer: A Pilot Study. *PM R*. 2021
15. Chen WT, Bansal S, **Chang SC** et al. Combined repeat laparoscopy and transanal endolumenal repair (hybrid approach) in the early management of postoperative colorectal anastomotic leaks: technique and outcomes. *Surg Endosc*. 2018

個人簡歷

一、基本資料

姓名：黃盈齊，Ying-Chi Huang

二、學歷

國立陽明大學醫學系 醫學士

三、經歷

1. 永康奇美醫院一般及消化系外科住院醫師
2. 永康奇美醫院一般及消化系外科總醫師
3. 永康奇美醫院一般及消化系外科臨床研究員
4. 永康奇美醫院大腸直腸外科總醫師
5. 永康奇美醫院大腸直腸外科臨床研究員

四、專長

1. 一般外科手術
2. 大腸直腸外科手術
3. 肛門手術

五、專科

1. 中華民國外科專科醫師
2. 中華民國大腸直腸醫學會專科醫師
3. 台灣消化系外科醫學會會員

六、論文及著述

1. Risk Factors for Development of Peri-Stomal Skin Complications: A Single-Center Retrospective Cohort Study; 黃盈齊, 周家麟, 李凱莉
2. 以迴盲腸腸套疊表現之盲腸瀰漫性大型 B 細胞淋巴瘤：個案病例報告; 黃盈齊, 黃亘毅, 周家麟, 田宇峯
3. Multiple Metastatic Melanoma Presenting as Multiple Gastrointestinal Perforation: A Case Report; 黃盈齊, 陳漢坤, 田宇峯, 陳明鎮